Denver, CO: The administration of plant-derived CBD is associated with sustained reductions in anxiety and short-term improvements in sleep, according to clinical trial data published in The Permanente Journal.
A team of investigators with the University of Colorado and Colorado State University College of Health and Human Sciences assessed the adjunctive use of CBD in 72 patients seeking improvements in sleep and anxiety-related disorders. Patients took daily doses of CBD in a capsule form for a period of one to three months. Subjects typically took 25mg per day, although some subjects consumed daily doses as high as 175mgs.
Subjects reported reductions in anxiety and improvements in sleep following 30 days of CBD dosing. Patients who continued taking CBD experienced sustained reductions in anxiety symptoms during the total three-month trial period. Sleep scores stabilized after one month. CBD administration was "well tolerated" among study subjects, "with few patients reporting side effects."
Authors concluded, "CBD displays promise as a tool for reducing anxiety in clinical populations. … Randomized and controlled trials are needed to provide definitive clinical guidance."
For more information, contact Paul Armentano, NORML Deputy Director. Full text of the study, "Cannabisiol in anxiety and sleep: A large case series," appears in The Permanente Journal.